Ann: Increased Scheme Consideration from Pfizer, page-208

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 208 Last

Share
Profile

Follow
JoCool

145 Posts.

116

15/06/22

13:47

Post #: 62012979
Share

Originally posted by TerribleTadpole: ↑

"It seems commercially naive to be looking at a sale of a Business Entity with out a full independent 3rd party valuation which includes the IP Suite"

Well now there is one. ResApp have the draft Independent Expert's Report already. It values the company at somewhere between 14.6c and 27.7c per share, or in other words at 21c ± 30%. At this point we have no idea of what the basis is of the valuation; whether IP is in or out, which markets were considered, what share of each market is estimated, the success-probability weighting, or anything.

ResApp must release the report with the scheme booklet for the takeover. There's nothing to say they couldn't release it earlier, independently of the takeover. It would be a valuable document for we shareholders in deciding how to vote on the takeover, and also for any potential competing bidder who could use the report as their first-pass due diligence.

For this reason I don't expect the board to release the report until they must, as doing so could represent a break of the implementation deed.

Expand

Thanks for your great work TT.
When you get the updated share register, can you look for any signs that Pfizer is accumulating Rap. It would make a lot of sense if they are. It would mean that T/O is being used to freeze the price as they are accumulating.

Cheers

RAP Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CC9

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

FFM

Firefly positioned for copper growth in Canada ahead of resource update

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 170 more messages in this thread...

First 208 Last

Add RAP (ASX) to my watchlist

Ann: Increased Scheme Consideration from Pfizer, page-208

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

Firefly positioned for copper growth in Canada ahead of resource update

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News